RxDoctor Payments Data

Douglas Lazzaro, MD

Ophthalmology · Brooklyn, NYNPI 1568445096

Payments from drug & device makers

$1,211in general payments, 2019–2025

Across 22 payments — averaging $55.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$569
  • Dompe US, Inc.$302
  • Mallinckrodt Hospital Products Inc.$200
  • Novartis$47
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$45
  • Aerie Pharmaceuticals, Inc.$25
  • plus $24 from 1 others

What the payments were for

  • Food & beverage$1,211100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,211 in reported general payments places this provider in the 50th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$254,885
Medicare patients
932
Services billed
2,730

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost61$34,163
RestasisCyclosporine38$32,632
Bepotastine Besilate43$10,587
BepreveBepotastine Besilate23$6,392
Travoprost22$5,114
SimbrinzaBrinzolamide/Brimonidine Tart18$5,064
Latanoprost503$4,441
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol12$4,273
CombiganBrimonidine Tartrate/Timolol14$3,869
Timolol Maleate96$3,651
Brimonidine Tartrate85$3,364
Brinzolamide25$3,205
Loteprednol Etabonate17$3,102
Cyclosporine14$3,092
Prednisolone Acetate59$2,467

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb, A Division Of Bausch Health US, LLCBepreve, Loteprednol Etabonate$45$9,49440 claims
AlconSimbrinza$569$5,06418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →